編者按：當地時間4月29日，ASCO官網公佈了今年5月29~31日將以線上會議形式舉行的ASCO 2020大會日程及摘要題目。
在消化腫瘤領域，此次大會有2項中國研究入選oral摘要演講。本文總結ASCO 2020在線會議日程以及消化腫瘤領域摘要、重磅研究及oral報告如下。
Abstract 4506：多納非尼對比索拉非尼作為晚期肝細胞癌一線治療：一項開放標籤、隨機、多中心Ⅱ/Ⅲ期臨床試驗
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Author(s):Feng Bi畢鋒（四川大學華西醫院）, Shukui Qin秦叔逵（東部戰區總醫院）, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen
Abstract 4507：阿帕替尼二線治療中國晚期肝細胞癌患者：一項隨機、安慰劑對照、雙盲、Ⅲ期研究
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma:A randomized, placebo-controlled, double-blind, phase III study.
Author(s):Qiu Li李秋（四川大學華西醫院）, Shukui Qin秦叔逵（東部戰區總醫院）, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan潘宏銘, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin
ASCO 2020在線會議日程
受COVID-19疫情影響，2020年美國臨床腫瘤學會年會（ASCO2020）將於美國東部時間2020年5月29~31日（以下所述時間均為美國東部時間，ET）以線上會議的形式舉行。讀者登陸ASCO會議圖書館（meetinglibrary.asco.org），按照24個疾病類型或其他軌跡搜索250多份oral摘要演講以及2500多份poster演講。
▲讀者可於在線日程中根據“Type”、“Track”或其他關鍵詞進行搜索
關鍵日期：
4月29日11:00——公佈會議日程（線上日程中包含了所有會議摘要題目）
5月13日17:00——大部分摘要將在ASCO會議圖書館公佈
5月28日17:00——公佈LBA摘要
5月29~31日——ASCO2020線上會議日程
會議日程計劃：
5月29日當天早上8:00開始，大會將按需提供Oral，Poster Discussion和 Poster等場次報告，以及其他臨床科學研討會；會議註冊者可在180天內獲得數百個演講視頻和幻燈。
5月30~31日的線上會議主要為開幕式（Opening Session）、重點會議（Highlights Sessions）、臨床科學專題研討會（Special Clinical Science Symposium）等內容。
消化腫瘤領域重磅研究及口頭報告目錄
LBA
LBA4——帕博利珠單抗對比化療治療高微衛星不穩定/錯配修復缺陷轉移性結直腸癌：Ⅲ期KEYNOTE-177研究
Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study
Session:Plenary Session
Author(s):Thierry Andre, Kai-Keen Shiu, et al.
Discussion of LBA4
Session:Plenary Session
Discussant:Michael J. Overman, MD| The University of Texas MD Anderson Cancer Center
胃腸道腫瘤——胃食管、胰腺、肝膽
Abstract 4500：曲妥珠單抗三聯療法治療HER2過表達食管腺癌：NRG Oncology/RTOG 1010
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010
Author(s):Howard Safran, Kathryn A. Winter, et al.
Abstract 4501：ramucirumab聯合FLOT方案對比FLOT方案圍手術期治療可切除食管胃腺癌(RAMSES/FLOT7)：德國AIO和意大利GOIM多中心隨機Ⅱ/Ⅲ期試驗的Ⅱ期部分結果
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
Author(s):Salah-Eddin Al-Batran, Ralf D. Hofheinz, et al.
Abstract 4502：曲妥珠單抗+帕妥珠單抗+FLOT方案對比FLOT方案圍手術期治療HER2陽性可切除食管胃腺癌患者：PETRARCA-AIO Ⅱ期研究最終結果
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
Author(s):Ralf D. Hofheinz, Georg Martin Haag, et al.
Abstract 4503：帕博利珠單抗對比紫杉醇治療既往治療過的PD-L1陽性晚期胃或胃食管交界部癌(GC)患者：Ⅲ期KEYNOTE-061試驗的更新
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
Author(s):Charles S. Fuchs, Mustafa zgürolu, et al.
Abstract 4504：SWOG S1505：圍手術期化療（peri-op CTx）+ mFOLFIRINOX對比吉西他濱/白蛋白結合紫杉醇（Gem/nabP）治療可切除胰腺導管腺癌的結果
SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).
Author(s):Davendra Sohal, Mai T. Duong, et al.
Abstract 4505：ESPAC-5F：即刻手術對比新輔助吉西他濱+卡培他濱或FOLFIRINOX或化放療（CRT）治療交界性可切除胰腺癌患者的4臂、前瞻性、多中心、國際隨機Ⅱ期試驗
ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
Author(s):Paula Ghaneh, Daniel H. Palmer, et al.
Abstract 4506：多納非尼對比索拉非尼作為晚期肝細胞癌一線治療：一項開放標籤、隨機、多中心Ⅱ/Ⅲ期臨床試驗
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Author(s):Feng Bi畢鋒（四川大學華西醫院）, Shukui Qin秦叔逵（東部戰區總醫院）, et al.
Abstract 4507：阿帕替尼二線治療中國晚期肝細胞癌患者：一項隨機、安慰劑對照、雙盲、Ⅲ期研究
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma:A randomized, placebo-controlled, double-blind, phase III study.
Author(s):Qiu Li李秋（四川大學華西醫院）, Shukui Qin秦叔逵（東部戰區總醫院）, et al.
Abstract 4508：一種新藥tremelimumab聯合度伐單抗治療晚期肝細胞癌的療效、耐受性和生物學活性
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Author(s):Robin K. Kelley, Bruno Sangro, et al.
胃腸道腫瘤——結直腸和肛門
Abstract 4000：曲妥珠單抗-deruxtecan(T-DXd; DS-8201)治療HER2表達的轉移性結直腸癌(mCRC)的Ⅱ期、多中心、開放標籤研究：DESTINY-CRC01
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Author(s):Salvatore Siena, Maria Di Bartolomeo, et al.
Abstract 4001：隨機、3臂、Ⅲ期研究BEACON CRC最新生存期結果：Encorafenib聯合西妥昔單抗±binimetinib對比研究者選擇的伊立替康+西妥昔單抗（對照）或FOLFIRI+西妥昔單抗（對照）治療BRAF V600E轉移性結直腸癌
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
Author(s):Scott Kopetz, Axel Grothey, et al.
Abstract 4002：FOLFOX+帕尼單抗對比5FU+帕尼單抗一線治療RAS-BRAF野生型轉移性結直腸癌早期患者：PANDA研究
First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.
Author(s):Sara Lonardi, Marta Schirripa, et al.
Abstract 4003：塞來昔布在5-FU、白細胞介素、奧沙利鉑（FOLFOX）的標準輔助治療Ⅲ期結腸癌中的作用：來自CALGB/SWOG 80702研究的結果
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.
Author(s):Jeffrey A. Meyerhardt, Qian Shi, et al.
Abstract 4004：Ⅲ期結腸癌患者奧沙利鉑和以氟嘧啶為基礎的輔助治療3個月對比治療6個月的OS和長期DFS：IDEA最終結果
Overall survival (OS) and long-term disease-free survival (DFS) of three versussix months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
Author(s):Alberto F. Sobrero, Thierry Andre, et al.
Abstract 4005：比較肝切除術後mFOLFOX6與單純肝切除術治療結直腸癌肝轉移的療效：一項隨機Ⅱ/Ⅲ期試驗
A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study.
Author(s):Yukihide Kanemitsu, Yasuhiro Shimizu, et al.
Abstract 4006：局部進展期直腸癌TME前短程放療後化療：RAPIDO隨機試驗
Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.
Author(s):Geke Hospers, Renu R. Bahadoer, et al.
Abstract 4007：局部進展期直腸癌患者mFOLFIRINOX對比術前同步放化療進行全程新輔助治療：UNICANCER GI試驗PRODIGE 23 III期試驗的最終結果
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
Author(s):Thierry Conroy, Najib Lamfichekh, et al.
Abstract 4008：直腸腺癌(OPRA)器官保留試驗的初步結果
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.
Author(s):Julio Garcia-Aguilar, Sujata Patil, et al.
閱讀更多 雲醫會 的文章
